Landos Biopharma, Inc. (LABP) Comparison with companies in other sectors?

Landos Biopharma, Inc. has a share price of 3.13M. You can analyze Landos Biopharma, Inc. (LABP) competitors across different market sectors through stock heatmaps.

What are LABP's NET and operating margins?

Landos Biopharma, Inc. (LABP) operating margin is around 0.00, and net profit margin is approximately 0.00 as of the latest reports.

In what way does LABP's earnings per share (EPS) trend reflect its financial momentum?

Landos Biopharma, Inc. (LABP) EPS is -4.00 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Landos Biopharma, Inc. is -5.73, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Landos Biopharma, Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Landos Biopharma, Inc. like P/E which is -9.48, P/B which is 6.15, and PEG which is 0.57. Compare them with sector averages to evaluate if the stock is priced fairly.

Landos Biopharma, Inc.

LABP•NASDAQ

Healthcare

Biotechnology

$22.93

$0.13(0.57%)

Fundamental Analysis of Landos Biopharma, Inc. (LABP)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$-4.00

P/E Ratio

-5.73

ROE

-0.55%

Net Margin

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$71.68M

Shares OutstandingTotal number of shares issued

$3.13M

Book Value/ShareNet worth per share

$3.73

Revenue/ShareAnnual revenue per share

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-4

Net MarginNet income as percentage of revenue

Operating MarginOperating income as percentage of revenue

ROEReturn on shareholders' equity

-54.66%

ROAReturn on total assets

-50.23%

ROCEReturn on capital employed

-67.40%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-2.17

Cash/ShareCash and equivalents per share

$4.68

FCF YieldFree cash flow as percentage of market cap

-18.79%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for LABPFinancial Ratios Analysis details for LABP are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for LABPSector Benchmarking details for LABP are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Landos Biopharma, Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Landos Biopharma, Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Landos Biopharma, Inc.'s unique business strengths and challenges.

Key Financial Metrics for Landos Biopharma, Inc.

For Landos Biopharma, Inc., essential financial indicators include EPS -4.00, PE -5.73, and ROE -0.55. These key ratios reveal insights into Landos Biopharma, Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Landos Biopharma, Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Landos Biopharma, Inc.

Metrics like Net Margin - and ROA -50.23% shed light on how well Landos Biopharma, Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Landos Biopharma, Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of Landos Biopharma, Inc.

Using ratios such as P/B Ratio 6.15 and PEG Ratio 0.57, investors can assess whether Landos Biopharma, Inc. is appropriately valued based on its financials and growth potential. These figures, combined with Landos Biopharma, Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Landos Biopharma, Inc.

Financial health indicators, such as Debt/Equity Ratio - and Cash Flow $-2.17, provide a snapshot of Landos Biopharma, Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Landos Biopharma, Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Landos Biopharma, Inc.

Investing in Landos Biopharma, Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Landos Biopharma, Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;